Cancer drug resistance as learning of signaling networks.

Dávid Keresztes¹, Márk Kerestély¹, Levente Szarka¹, Borbála M Kovács¹, Klára Schulc², Dániel V Veres³, Peter Csermely⁴

¹Department of Molecular Biology, Semmelweis University, Budapest, Hungary.

²Department of Molecular Biology, Semmelweis University, Budapest, Hungary; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.

³Department of Molecular Biology, Semmelweis University, Budapest, Hungary; Turbine Simulated Cell Technologies, Budapest, Hungary.

⁴Department of Molecular Biology, Semmelweis University, Budapest, Hungary. Electronic address: csermely.peter@semmelweis.hu.

PubMed DOI

Abstract

Drug resistance is a major cause of tumor mortality. Signaling networks became useful tools for driving pharmacological interventions against cancer drug resistance. Signaling datasets now cover the entire human cell. Recently, network adaptation became understood as a learning process. We review rapidly increasing evidence showing that the development of cancer drug resistance can be described as…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.